Downregulated Plasma miR-92a Levels Have Clinical Impact on Multiple Myeloma and Related Disorders

Blood Cancer Journal - United States
doi 10.1038/bcj.2011.51
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Hypercalcemia Induced With the Plasma Levels of Parathyroid Hormone-Related Peptide in Multiple Myeloma.

Internal Medicine
Internal MedicineMedicine
2000English

Significance of M-Components in Plasma Cell Myeloma and Related Disorders

Tohoku Journal of Experimental Medicine
BiochemistryMedicineGeneticsMolecular Biology
1970English

Cytogenetic Study of 48 Patients With Multiple Myeloma and Related Disorders

Journal of clinical and experimental hematopathology : JCEH
Medicine
2003English

Clinical Relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in Colorectal Cancer

BMC Cancer
Cancer ResearchOncologyGenetics
2012English

Clinical Impact of Serum Soluble SLAMF7 in Multiple Myeloma

Oncotarget
Oncology
2018English

Profound Impact of Sample Processing Delay on Gene Expression of Multiple Myeloma Plasma Cells

BMC Medical Genomics
Genetics
2015English

Bortezomib: The Evidence of Its Clinical Impact in Multiple Myeloma

Core Evidence
MedicineReviewsReferencesPharmacology
2006English

miR-92a Enhances Recombinant Protein Productivity in CHO Cells by Increasing Intracellular Cholesterol Levels

BMC Proceedings
BiochemistryMedicineGeneticsMolecular Biology
2015English

Clinical Implications of C-Maf Expression in Plasma Cells From Patients With Multiple Myeloma

Experimental Hematology and Oncology
Cancer ResearchOncologyHematology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy